새로 진단된 소아 HGG 및 DIPG 및 재발성 수모세포종 치료를 위한 CMV 항원을 표적으로 하는 PEP-CMV 백신
새로 진단된 소아 고급 신경아교종 및 미만성 내재 교교 신경아교종 및 재발성 수모세포종에 대한 CMV 항원을 표적으로 하는 새로운 펩티드 백신(PEP-CMV)의 2상 시험
This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) as well as recurrent medulloblastoma (MB).
PEP-CMV is a vaccine mixture of a peptide referred to as Component A. Component A is a synthetic long peptide (SLP) of 26 amino acid residues from human pp65. The SLPs encode multiple potential class I, class II, and antibody epitopes across several haplotypes. Component A will be administered as a stable water:oil emulsion in Montanide ISA 51.
Funding Source - FDA OOPD
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
This phase II clinical trial will have 3 strata in order to assess the efficacy of a highly immunogenic CMV-directed peptide vaccines in children with (1) recurrent medulloblastoma (rMB), (2) newly-diagnosed high-grade gliomas (HGG) and (3) newly-diagnosed diffuse intrinsic pontine glioma (DIPG). Each stratum will run independently with a different endpoint and statistical design.
Within each stratum, the populations that may be used for analysis are defined as:
- Safety Analysis: Patients who receive at least 1 dose of the treatment will be used for safety analyses.
- Efficacy Analysis: Patients who receive at least 1 dose of the treatment will be used for efficacy analyses.
Stratum I: Patients with recurrent medulloblastoma with measurable disease (see eligibility) can be enrolled at any point following recurrence regardless of any prior therapy. For the purpose of this study, recurrence will be defined as a new lesion confirmed by biopsy or resection, positive cerebrospinal fluid (CSF) cytology, or recurrent/progressive tumor on MRI.
Strata II [CLOSED on 19Aug2026] and III: Patients with newly-diagnosed high-grade glioma [CLOSED on 19Aug2026] or DIPG may be enrolled any time within 42 days after completing radiation.
Cycle 1 (Induction cycle) is 77±2 days. Patients will receive one course of temozolomide 200 mg/m2/day x 5 days on Days 1-5 of cycle 1 and receive PEP-CMV vaccine intradermally at dose level 1 (250 μg/m2 ) on Days 21, 35 ±2 days, and 49 ±2 days. After the induction cycle which is 77 ± 2 days, each subsequent cycle is 28 days. Starting in cycle 2, PEP-CMV vaccine is administered intradermally every 28 days on day 1 of each course. Patient can continue to receive PEP-CMV every 28 days for a total of 24 cycles.
Patients will receive a tetanus (Td) booster (Td 5 flocculation units, Lf) at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine (Td 1 Lf, in 0.4 mL of saline) delivered i.d. at the RIGHT groin site of the vaccine injection 6-24 hours prior to the first vaccine on day 21.
The PEP-CMV vaccine will be administered as follows: 250 µg/m2 (up to a maximum of 500 µg) of Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Kelsey H Troyer, PhD
- 전화번호: 6147223284
- 이메일: kelsey.troyer@nationwidechildrens.org
연구 장소
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- 모병
- Children's Hospital Colorado
-
연락하다:
- Holly Lindsay, MD
- 전화번호: 720-777-0461
- 이메일: holly.lindsay@childrenscolorado.org
-
수석 연구원:
- Holly Lindsay, MD
-
-
District of Columbia
-
Washington D.C., District of Columbia, 미국, 20010
- 모병
- Children's National Medical Center
-
연락하다:
- Eugene Hwang, MD
- 전화번호: 202-476-5046
- 이메일: ehwang@childrensnational.org
-
수석 연구원:
- Eugene Hwang
-
-
Florida
-
Miami, Florida, 미국, 33155
- 모병
- Nicklaus Children's Hospital
-
연락하다:
- Ziad Khatib, MD
- 전화번호: 305-662-8360
- 이메일: ziad.khatib@nicklaushealth.org
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- 아직 모집하지 않음
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
수석 연구원:
- Ashley Plant, MD
-
연락하다:
- Ashley Plant, MD
- 전화번호: 312-227-4090
- 이메일: aplant@luriechildrens.org
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02215
- 아직 모집하지 않음
- Dana-Farber Cancer Institute
-
수석 연구원:
- Karen Wright, MD
-
연락하다:
- Karen Wright, MD
- 전화번호: 617.632.4309
- 이메일: KarenD_wright@dfci.harvard.edu
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48109
- 모병
- C.S. Mott Children's Hospital
-
연락하다:
- John Prensner, MD
- 전화번호: 8669094449
- 이메일: prensner@med.umich.edu
-
-
Missouri
-
St Louis, Missouri, 미국, 63110
- 모병
- St. Louis Children's Hospital
-
수석 연구원:
- Eric M Thompson, MD
-
연락하다:
- Eric M Thompson, MD
- 이메일: pedshemonctrialreferral@wustl.edu
-
-
North Carolina
-
Durham, North Carolina, 미국, 27710
- 모병
- Duke Cancer Center
-
수석 연구원:
- Daniel Landi, MD
-
연락하다:
- Daniel Landi, MD
- 전화번호: 919-684-5013
- 이메일: pedsneuronc@duke.edu
-
-
Ohio
-
Cincinnati, Ohio, 미국, 45229
- 모병
- Cincinnati Children's Hospital Medical Center
-
수석 연구원:
- Peter de Blank, MD
-
연락하다:
- Peter de Blank, MD
- 전화번호: 513-517-2068
- 이메일: Peter.deBlank@cchmc.org
-
Columbus, Ohio, 미국, 43205
- 모병
- Nationwide Children's Hospital
-
수석 연구원:
- Maryam Fouladi, MD
-
연락하다:
- Kennedy Thompson
- 전화번호: 614-722-5043
- 이메일: kennedy.thompson@nationwidechildrens.org
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- 아직 모집하지 않음
- Children's Hospital of Philadelphia
-
연락하다:
- Michael J Fisher, MD
- 전화번호: 215-590-5188
- 이메일: fisherm@email.chop.edu
-
수석 연구원:
- Michael J Fisher, MD
-
-
Texas
-
Houston, Texas, 미국, 77030
- 모병
- Texas Children's Hospital
-
연락하다:
- Patricia Baxter, MD
- 전화번호: 832-824-4681
- 이메일: pabaxter@txch.org
-
수석 연구원:
- Patricia Baxter, MD
-
-
Washington
-
Seattle, Washington, 미국, 98105
- 모병
- Seattle Children's Hospital
-
연락하다:
- Sarah Leary, MD
- 전화번호: 206-987-2106
- 이메일: sarah.leary@seattlechildrens.org
-
수석 연구원:
- Sarah Leary, MD
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria for patients with recurrent /progressive medulloblastoma (stratum I)
-
Age: Patients must be ≥3 and ≤39 years of age at the time of study enrollment
-
Diagnosis: Patients must have a diagnosis of medulloblastoma that is recurrent, progressive or refractory. All patients must have histological verification of a medulloblastoma, at original diagnosis or relapse.
• Patients must have measurable disease defined as a lesion that can be measured in two perpendicular diameters on MRI.
-
Metastatic Disease: Patients with M+ disease are eligible.
-
Performance Status:
Karnofsky ≥ 50% for patients >16 years of age or Lansky ≥ 50 for patients ≤ 16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
-
Prior Therapy:
-
Radiotherapy: prior radiotherapy requirements Patients must have received prior disease-directed therapy including radiotherapy for their diagnosis of medulloblastoma unless patients are less than 4 years of age at the time of enrollment.
For those less than 4 years of age at the time of enrollment, prior disease directed therapy does not have to include prior radiotherapy.
Patients must have had their last fraction of:
- Craniospinal irradiation, total body irradiation or radiation to ≥ 50% of pelvis > 3 months prior to enrollment.
- Focal irradiation > 4 weeks prior to enrollment
-
Myelosuppressive anticancer therapy: Patients must have received their last dose of myelosuppressive anticancer therapy at least 21 days prior to enrollment
-
Immunotherapy: Patients must have received their last dose of any immunotherapy agents at least 30 days prior to enrollment
-
Non-myelosuppressive anticancer agents: Patients must have received their last dose of non-myelosuppressive anticancer agents at least 7 days prior to study enrollment.
-
Antibodies: Patients must have received their last dose of any antibodies at least 21 days prior to enrollment.
-
Hematopoietic growth factors: Patients must have received their last dose of hematopoietic growth factors at least 14 days prior to enrollment for a long-acting growth factor (e.g. pegfilgrastim) or 7 days prior to enrollment for short-acting growth factor.
-
Autologous stem cell infusion: At least 90 days must have elapsed after an autologous stem cell infusion
-
-
Organ Function Requirements:
-
Adequate bone marrow function defined as:
- ANC (Absolute neutrophil count) ≥ 1000/µl.
- Platelets ≥ 100,000/µl. (may be supported)
- Hemoglobin > 8 g/dL. (may be supported)
-
Adequate Renal Function defined as: Creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73 m2 or A serum creatinine based on age/gender as follows:
Age: Maximum Serum Creatinine (mg/dL)
- 2 to < 6 years: 0.8 (Male) 0.8 (Female)
- 6 to < 10 years: 1 (Male) 1 (Female)
- 10 to < 13 years: 1.2 (Male) 1.2 (Female)
- 13 to < 16 years: 1.5 (Male) 1.4 (Female)
- ≥ 16 years: 1.7 (Male) 1.4 (Female)
-
Adequate Liver Function Defined as
- Total bilirubin ≤1.5 times institutional ULN
- AST(SGOT) ≤3 × institutional upper limit of normal
- ALT(SGPT) ≤3 × institutional upper limit of normal
-
Adequate Neurological Function Defined as
- Patients with neurological deficits should have deficits that are stable for a minimum of 2 weeks prior to enrollment.
- Patients with current seizure disorders may be enrolled if seizures are well- controlled on antiepileptic therapies.
-
Patients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for three months after drug cessation.
-
Signed informed consent according to institutional guidelines must be obtained prior to enrollment.
-
Inclusion Criteria for Patients with Newly-Diagnosed High-Grade Gliomas (HGG) (stratum II, CLOSED on 19Aug2026) and Newly-Diagnosed (DIPG) (stratum III)
-
Age: Patients must be ≥3 and ≤39 years of age at the time of study enrollment
-
Diagnosis
-
Stratum II [CLOSED on 19Aug2026]: patients must have histologically confirmed, newly-diagnosed HGG (such as anaplastic astrocytoma, glioblastoma, H3K27-altered DMG).
- Patients with a newly-diagnosed HGG must enroll within 6 weeks of their final dose of standard radiation therapy with or without chemotherapy.
- Patients with primary spinal cord tumors are eligible
-
Stratum III: Patients with a newly-diagnosed DIPG:
- Patients with a radiographically typical DIPG, defined as a tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons, are eligible without histologic confirmation.
- Patients with brainstem lesions that do not meet these radiographic criteria will be eligible if there is histologic confirmation of an infiltrating astrocytoma WHO grades II-IV.
-
-
Metastatic Disease: Patients with M+ disease are eligible.
-
Performance Status:
Karnofsky ≥ 50 for patients > 16 years of age and Lansky ≥ 50 for patients ≤ 16 years of age (See Appendix I). Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
-
Prior Therapy requirements: Patients must have received no prior therapy other than surgery, radiation, chemotherapy during radiotherapy and/or steroids (dexamethasone with goal to wean dexamethasone throughout protocol therapy).
Patients with a newly diagnosed high-grade glioma or DIPG must enroll within 6 weeks of their final dose of standard of care radiation therapy with or without chemotherapy.
- Patients with HGG or DIPG are permitted, but not required, to have received chemotherapy during radiation. Bevacizumab is permitted prior to enrollment in patients with DIPG or HGG. Patients must have received their last dose of bevacizumab at least 14 days prior to enrollment.
- For HGG patients, Patients must have received radiotherapy at a standard dose of 54-59.4 Gy in 1.8 Gy fractions for approximately 6 weeks with an acceptable variance of 10%. Radiation therapy must have begun no later than 42 days after the date definitive surgery.
- For patients with DIPG, Patients must have received radiotherapy at a standard dose of radiotherapy of 54 Gy in 1.8 Gy daily fractions for approximately 6 weeks with an acceptable variance rate of 10%. Radiation therapy must have begun no later than 42 days after the date of radiographic diagnosis or biopsy
- For patients with spinal cord HGG: Patients must have received radiotherapy at a standard dose of 45-54 Gy in 1.8 Gy fractions for approximately 6-7 weeks with an acceptable variance of 10%
- For patients with metastatic disease: Patients may have received standard dose CSI
-
Organ Function Requirements:
-
Adequate bone marrow function defined as • ANC (Absolute neutrophil count) ≥ 1000/µl.
• Platelets ≥ 100,000/µl. (may be supported)
• Hemoglobin > 8 g/dL. (may be supported)
-
Adequate Renal Function defined as: Creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73 m2 or A serum creatinine based on age/gender as follows:
Age: Maximum Serum Creatinine (mg/dL)
• 2 to < 6 years: 0.8 (Male) 0.8 (Female)
• 6 to < 10 years: 1 (Male) 1 (Female)
• 10 to < 13 years: 1.2 (Male) 1.2 (Female)
• 13 to < 16 years: 1.5 (Male) 1.4 (Female)
• ≥ 16 years: 1.7 (Male) 1.4 (Female)
-
Adequate Liver Function Defined as:
• Total bilirubin ≤1.5 times institutional ULN
- AST(SGOT) ≤3 × institutional upper limit of normal
- ALT(SGPT) ≤3 × institutional upper limit of normal
-
Adequate Neurological Function Defined as:
-
Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to enrollment.
d. Patients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study.
e. Signed informed consent according to institutional guidelines must be obtained prior to registration and for 3 months after drug cessation.
Exclusion Criteria for all strata:
-
Pregnancy or Breast-Feeding:
- Pregnant or breast-feeding women will not be entered on this study due to known or unknown risks of fetal and teratogenic adverse events as seen in animal/human studies. Pregnancy tests must be obtained in girls who are post-monarchal. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
- Pregnancy Prevention Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for 3 months after drug cessation.
-
Study Specific:
- Active infection requiring treatment
- Patients with malignancy related to HIV or solid organ transplant: known history of HIV, HBV surface antigen positivity or positive HCV antibody are not eligible. Viral testing is not required unless clinically indicated in patients without a known history
- Known immunosuppressive disease
- Patients with active renal, cardiac (congestive cardiac failure, myocardial infarction, myocarditis), or moderate to severe pulmonary problems generally defined by need for medical intervention (e.g., oxygen, medications) and/or limiting activities of daily living (generally CTCAE Grade 2 or higher) or shortness of breath with limited exertion are not eligible. Pulmonary conditions include (but are not limited to) COPD, asthma, and hemi-pneumectomy
- Patients receiving concomitant immunosuppressive agents for medical conditions; inhaled corticosteroids for asthma are allowed.
- Patients receiving concomitant tumor-directed therapy
- Patients receiving any other investigational drug therapy.
- Patients on dexamethasone > 0.1 mg/Kg/day up to maximum dose of 4 mg/day or equivalent.
- Patients with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction).
- Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
- Patients at high risk for imminent neurologic decline due to extensive bulk disease, midline shift, or herniation on MRI. These patients should be discussed with the study chairs.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: PEP-CMV
Participants will receive standard chemotherapy with temozolomide for five days, followed by the study vaccine, PEP-CMV, on day 21. Participants will receive a tetanus diphtheria (Td) booster vaccine and a small dose Td preconditioning vaccine to prepare their immune system to receive their first PEP-CMV vaccine. Participants will receive the first 3 PEP-CMV vaccines every 2 weeks, and after the third vaccine, the rest of the vaccines will be given monthly. The first cycle is 77 days and all subsequent cycles are 28 days. The PEP-CMV vaccine may be received for up to 24 cycles. |
The PEP-CMV vaccine will be administered as follows: 250 µg/m2 (up to a maximum of 500 µg) of Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin. Patients will receive one course of temozolomide 200 mg/m2/day x 5 days on Days 1-5 of cycle 1
다른 이름들:
Patients will receive a tetanus (Td) booster (Td 5 flocculation units, Lf) at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine (Td 1 Lf, in 0.4 mL of saline) delivered i.d. at the RIGHT groin site of the vaccine injection 6-24 hours prior to the first vaccine on day 21.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
4-mo PFS in patients with recurrent medulloblastoma
기간: 4 months
|
To determine the progression-free survival (PFS) at 4 months in pediatric or young adult patients with recurrent medulloblastoma treated with PEP-CMV. |
4 months
|
|
1-yr OS in patients with newly diagnosed DIPG
기간: one year
|
To estimate the 1-year Overall Survival (OS) distribution in patients with newly diagnosed DIPG treated with radiotherapy followed by PEP-CMV |
one year
|
|
1-yr PFS in patients with newly diagnosed HGG
기간: one year
|
To estimate the 1-year Progression Free Survival (PFS) distribution in patients with newly diagnosed HGG treated with radiotherapy followed by PEP-CMV |
one year
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
ORR in patients with recurrent medulloblastoma
기간: From Day 1 of treatment through 30 days following end of protocol treatment
|
To determine the objective response rate (ORR) = partial response (PR) + complete response (CR) in patients with recurrent medulloblastoma treated with PEP-CMV |
From Day 1 of treatment through 30 days following end of protocol treatment
|
|
PFS in patients with recurrent medulloblastoma
기간: one year
|
To determine the 1-year Progression Free Survival (PFS) in patients with recurrent Medulloblastoma treated with PEP-CMV. |
one year
|
|
OS in patients with newly diagnosed HGG by PEP-CMV
기간: 2 years
|
To determine the 2-year Overall Survival (OS) in patients newly diagnosed with HGG treated with PEP-CMV. |
2 years
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Maryam Fouladi, MD, Nationwide Children's Hospital
- 연구 의자: Daniel Landi, MD, Duke Cancer Center
- 연구 의자: Eric M Thompson, MD, Washington University - St. Louis Children's Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 뇌 질환
- 중추신경계 질환
- 신경계 질환
- 부위별 신생물
- 신생물
- 조직학적 유형에 따른 신생물
- 신생물, 선상 및 상피
- 신생물, 신경상피
- 신경외배엽 종양
- 신생물, 생식 세포 및 배아
- 신생물, 신경 조직
- 신경계 신생물
- 신경외배엽 종양, 원시
- 중추신경계 신생물
- 뇌 신생물
- 뇌간 신생물
- 천막하 신생물
- 미만성 내재 교교 신경아교종
- 신경교종
- 수모세포종
- 유기 화학 물질
- 이종 사이 클릭 화합물, 1- 링
- 이종 사이 클릭 화합물
- Azoles
- 다 카르 바진
- 트리아 젠
- 이미 다졸
- 생물학적 제품
- 복잡한 혼합물
- 박테리아 백신
- 백신
- 디프테리아 톡소이드
- 톡소이드
- 파상풍 톡소이드
- 백신, 결합
- 테모졸로마이드
- 디프테리아-테타니아 백신
기타 연구 ID 번호
기타 연구 ID 번호
- CONNECT1906
- R01FD007283 (미국 FDA 승인/계약)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .